*The LigaSure™ XP Maryland jaw device is indicated for use in general surgery and such surgical specialties as colorectal, bariatric, urologic, vascular, thoracic, and gynecologic.
**Thick tissue is defined as non-dissected vascular tissue or fatty tissue
‡Compared to their current preferred device; 21 of 23 surgeons agreed during clinical procedures. §24 out of 29 surgeons agree.
Ω28 out of 29 surgeons agree.
††Compared to legacy LigaSure(TM) devices
‡‡ Bench tissue may not be indicative of clinical tissue performance
§ LigaSure XP Maryland Jaw length & aperture(23.368mm & 14.437mm) vs LigaSure™ Maryland length & aperture(20.523mm & 12.344mm) as measured from device tip to tissue stop.
§§ 29 out of 29 surgeons agree
1.Based on internal report #RE00457416 Rev A, Product introduction report: LigaSure™ XP Maryland jaw sealer/divider. May 2023.
2. Based on internal report #RE00442444 Rev A, Comparison of the renal artery bench bundle burst pressure performance with the LigaSure™ XP Maryland jaw sealer/ divider, Voyant™* Maryland Fusion, Enseal™* X1 curved jaw, and LigaSure™ LF19XX devices. Jan. 23, 2023.
3.Based on internal report #RE00372649 Rev A, Archer surgeon summative evaluation report. March 22, 2022.
4.Based on internal report #RE00376094 Rev A, LigaSure™ XP Maryland jaw sealer/divider surgeon validation marketing report. Dec. 7–9 and 14–16, 2021.
5. Based on internal test report RE00455509 RevB Ligasure Maryland XP Competitive Analysis.
6. Based on COGNOS and historical sales data for Advanced Energy through Sept. FY20FY01–FY20.
